BioSpace News Archive

The AccumTM technology platform was initially designed to enhance the accumulation of specific proteins, antibodies (ADCs) or antigen in target cells. Studies conducted by Defence revealed a strong therapeutic function for AccumTM when delivered on its own.

Each Unit shall consist of one common share of the Company and one-half of one common share purchase warrant (each a “Warrant”).

AiPharma Global Holdings LLC (“AiPharma”), a private biopharmaceutical research, development, and commercialization company, and Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases, announced today a strategic alliance to advance the global development of Avigan®/Reeqonus™

Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced that Robert Brown has joined the company as Chief Financial Officer, starting immediately.

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection.

Nexxt Spine, LLC, an industry leader in the surgical treatment of spinal disorders, announces the commercial launch of the NEXXT MATRIXX® Cervical Stand-Alone System.

Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Teriflunomide Tablets (generic for Aubagio®).

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it will report third quarter 2021 financial results on Thursday, October 21, 2021, before the market opens.

The DeGregorio Family Foundation has awarded $250,000 to Bryson Katona, MD, PhD, Assistant Professor of Medicine and Director at the Gastrointestinal Cancer Genetics Program at University of Pennsylvania Perelman School of Medicine.

NeuroWave Systems Inc. is pleased to announce the FDA clearance of its NeuroSENSE® NS-901 Monitor – a new generation brain function monitor for assessing the adequacy of anesthesia and sedation in clinical settings.